CYP7A1 and metabolic dysfunction-associated steatohepatitis: A subsequent study provided deeper mechanistic insight, showing that diosgenin alleviated NASH by increasing the abundance of Clostridia and fecal BSH activity to modulate BA metabolism, while simultaneously activating hepatic FXR/SHP and intestinal FXR/FGF15 signaling to suppress CYP7A1 (Yan et al., 2023).